Answers are grounded in this paper and cite their sources.
OBJECTIVE: The (PERIOdontitis and Coronary Artery Disease) PERIOCAD study aims to investigate the association between periodontitis and coronary artery disease (CAD) in patients undergoing cardiac computed tomography angiography (CCTA) and the effectiveness of early versus late periodontitis (PD) treatment on systemic inflammation and CAD progression. BACKGROUND: PD and CAD are common diseases, sharing underlying molecular mechanisms, like systemic inflammation and endothelial dysfunction. Epidemiological and genetic studies suggest a strong link between PD and CAD. Yet, it remains unclear whether treatment of periodontitis may attenuate progression of arteriosclerosis. CCTA enables reproducible quantitative assessment of coronary plaque volumes and composition, providing metrics for both cross-sectional associations and longitudinal changes of plaque burden. METHODS: PERIOCAD is a prospective, randomized, controlled trial (RCT) aiming to enroll 200 patients who undergo clinically indicated CCTA. All participants will undergo comprehensive periodontal status assessment and patients diagnosed with PD (estimated n = 100) will be randomized 1:1 to either early, systematic PD therapy (intervention arm) or delayed care after 2 years (control arm). CCTA analysis will include quantitative plaque volumes and composition, assessment of high-risk plaque features and evaluation of pericoronary adipose tissue attenuation (PCAT). Cardiac and inflammatory biomarkers will be assessed at baseline and after 24 months. Follow-up evaluations are scheduled at 12 and 24 months to reassess periodontal status. In addition, changes in plaque burden will be longitudinally assessed in case of clinically indicated repeat CCTA scans. The primary endpoint is the influence of periodontal treatment on cardiac and inflammatory biomarkers at 24 months. Secondary endpoints include major adverse cardiovascular events during follow-up, changes in plaque parameters and PCAT on serial CCTA, and associations between CCTA metrics and PD at baseline. DISCUSSION: PERIOCAD is expected to provide unique insights regarding the relationship between PD and CAD, being to our knowledge the first RCT to investigate the impact of PD therapy on systemic inflammation and CAD progression in symptomatic patients. Our findings could have significant implications for interdisciplinary cardiovascular disease prevention strategies and public health policies. TRIAL REGISTRATION: German Clinical Trials Register DRKS00038470 (Date of registration:2025-11-24).
No takes yet. Share an insight, caveat, or question.
Weichsel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: